Literature DB >> 3005214

Immunoactive peptides, FK 156 and FK 565. IV. Activation of mouse macrophages.

Y Watanabe, S Tawara, Y Mine, H Kikuchi.   

Abstract

We investigated the effects of the immunoactive peptides, FK 156 and FK 565, on functions of mouse macrophages. FK 156 and FK 565 given parenterally or orally to mice enhanced spreading of peritoneal macrophages, phagocytosis of latex particles and intracellular killing of bacteria by peritoneal macrophages. FK 156 and FK 565 also enhanced the production of superoxide anion and lysosomal enzyme activities of macrophages. The peptides also activated mouse spleen macrophages, and the kinetics of this activation differed from that of the peritoneal macrophages. In addition, both drugs directly enhanced the production of superoxide anion by mouse peritoneal macrophages treated in vitro and enhanced the functions of peritoneal macrophages of athymic nude mice. Both these phenomena suggest that direct activation might be one of the mechanisms of macrophage activation by the peptides.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3005214     DOI: 10.7164/antibiotics.38.1781

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  8 in total

1.  Immunomodulatory and therapeutic properties of FK-565 in mice.

Authors:  J E Talmadge; B Lenz; M Schneider; H Phillips; C Long
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  A macrophage-stimulating compound from a screen of microbial natural products.

Authors:  Julie A Perry; Kalinka Koteva; Chris P Verschoor; Wenliang Wang; Dawn M E Bowdish; Gerry D Wright
Journal:  J Antibiot (Tokyo)       Date:  2014-07-02       Impact factor: 2.649

3.  Effect of anticancer drugs on the release of interferon gamma in vitro.

Authors:  K Ahmed; P H van der Meide; J L Turk
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Effect of anticancer agents neothramycin, aclacinomycin, FK-565 and FK-156 on the release of interleukin-2 and interleukin-1 in vitro.

Authors:  K Ahmed; J L Turk
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  Structure-activity relationships in nucleotide oligomerization domain 1 (Nod1) agonistic γ-glutamyldiaminopimelic acid derivatives.

Authors:  Geetanjali Agnihotri; Rehman Ukani; Subbalakshmi S Malladi; Hemamali J Warshakoon; Rajalakshmi Balakrishna; Xinkun Wang; Sunil A David
Journal:  J Med Chem       Date:  2011-02-07       Impact factor: 7.446

6.  Effect of anticancer drugs on the release of tumour necrosis factor in vitro.

Authors:  S I Hasan; K Ahmed; J L Turk
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

7.  Nucleotide-Binding Oligomerization Domain 1/Toll-Like Receptor 4 Co-Engagement Promotes Non-Specific Immune Response Against K562 Cancer Cells.

Authors:  Samo Guzelj; Žiga Jakopin
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988

8.  Synergistic effects of NOD1 or NOD2 and TLR4 activation on mouse sickness behavior in relation to immune and brain activity markers.

Authors:  Aitak Farzi; Florian Reichmann; Andreas Meinitzer; Raphaela Mayerhofer; Piyush Jain; Ahmed M Hassan; Esther E Fröhlich; Karin Wagner; Evelin Painsipp; Beate Rinner; Peter Holzer
Journal:  Brain Behav Immun       Date:  2014-09-11       Impact factor: 7.217

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.